Scott C. Bell mainly investigates Cystic fibrosis, Microbiology, Pseudomonas aeruginosa, Internal medicine and Immunology. His Cystic fibrosis research integrates issues from Pathology, Lung and Intensive care medicine. His biological study spans a wide range of topics, including 16S ribosomal RNA, Burkholderia pseudomallei, Multilocus sequence typing, Sequence analysis and Virulence.
His Pseudomonas aeruginosa research includes themes of Genotype, Pulsed-field gel electrophoresis, Sputum and Antibiotic sensitivity. His work deals with themes such as Gastroenterology, Endocrinology and Surgery, which intersect with Internal medicine. His Surgery research is multidisciplinary, incorporating perspectives in Respiratory disease and Placebo.
Scott C. Bell mainly focuses on Cystic fibrosis, Microbiology, Internal medicine, Pseudomonas aeruginosa and Intensive care medicine. His research in Cystic fibrosis tackles topics such as Immunology which are related to areas like Lung. Scott C. Bell combines subjects such as Genome, Gene and Burkholderia, Bacteria with his study of Microbiology.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Endocrinology. The concepts of his Pseudomonas aeruginosa study are interwoven with issues in Polymerase chain reaction and Genotyping, Multilocus sequence typing, Genotype. His research in Intensive care medicine intersects with topics in Lung transplantation, Disease, Pediatrics and Bronchiectasis.
Scott C. Bell mostly deals with Cystic fibrosis, Internal medicine, Microbiology, Pseudomonas aeruginosa and Antibiotic resistance. Specifically, his work in Cystic fibrosis is concerned with the study of Ivacaftor. His studies in Internal medicine integrate themes in fields like Gastroenterology and Transmission.
The study incorporates disciplines such as Stenotrophomonas, Genome, Stenotrophomonas maltophilia and Bacteria in addition to Microbiology. Scott C. Bell interconnects Lung, Bronchiectasis, Sputum, Respiratory infection and COPD in the investigation of issues within Pseudomonas aeruginosa. His study looks at the intersection of Intensive care medicine and topics like Disease with Tertiary healthcare.
Scott C. Bell spends much of his time researching Cystic fibrosis, Antibiotic resistance, Intensive care medicine, Ivacaftor and Randomized controlled trial. His Cystic fibrosis study introduces a deeper knowledge of Internal medicine. His studies deal with areas such as Pseudomonas aeruginosa and Disease as well as Antibiotic resistance.
His Intensive care medicine study combines topics in areas such as Antimicrobial stewardship, Disease burden and Mycobacterium tuberculosis. He has researched Ivacaftor in several fields, including Gastroenterology, Treatment results and Body mass index. His Randomized controlled trial research incorporates themes from Lung transplantation, Spirometry, Pulmonary function testing and Arterial blood.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation
Bonnie W. Ramsey;Jane Davies;N. Gerard McElvaney;Elizabeth Tullis.
The New England Journal of Medicine (2011)
European Cystic Fibrosis Society Standards of Care: Best Practice guidelines
Alan R. Smyth;Scott C. Bell;Snezana Bojcin;Mandy Bryon.
Journal of Cystic Fibrosis (2014)
Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: A randomised trial
J Wolter;S Seeney;S Bell;S Bowler.
ECFS best practice guidelines: the 2018 revision
Carlo Castellani;Alistair J.A. Duff;Alistair J.A. Duff;Scott C. Bell;Harry G.M. Heijerman.
Journal of Cystic Fibrosis (2018)
Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.
Josephine M Bryant;Josephine M Bryant;Dorothy M Grogono;Dorothy M Grogono;Daniela Rodriguez-Rincon;Isobel Everall.
Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals
David J. Lederer;Scott C. Bell;Richard D. Branson;James D. Chalmers.
Annals of the American Thoracic Society (2019)
Activation and adoptive transfer of Epstein–Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
Rajiv Khanna;Scott Bell;Martina Sherritt;Andrew Galbraith.
Proceedings of the National Academy of Sciences of the United States of America (1999)
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
Michael P Boyle;Scott C Bell;Michael W Konstan;Susanna A McColley.
The Lancet Respiratory Medicine (2014)
Genetic modifiers of liver disease in cystic fibrosis.
Jaclyn R. Bartlett;Kenneth J. Friedman;Simon C. Ling;Rhonda G. Pace.
The future of cystic fibrosis care: a global perspective
Scott C Bell;Marcus A Mall;Hector Gutierrez;Milan Macek.
The Lancet Respiratory Medicine (2020)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: